Molecular Diagnostics Equipment and Reagent Market Size & Share 2026-2035

Molecular Diagnostics Equipment and Reagent Market Size

The global molecular diagnostics equipment and reagent market was valued at USD 18.5 billion in 2025 and is projected to grow from USD 19.8 billion in 2026 to USD 38.6 billion by 2035, expanding at a CAGR of 7.6%, according to the latest report published by Global Market Insights Inc. This substantial growth is driven by several key factors, including technological advances and increasing awareness towards early disease diagnosis globally, escalating demand for POC diagnostics and increasing geriatric population base.

Molecular diagnostics equipment and reagents comprise instruments, analyzers, assay kits, and consumables used to detect, identify, and monitor diseases and biological conditions through the analysis of DNA, RNA, and other molecular biomarkers. These products support applications in clinical diagnostics, infectious disease testing, oncology, genetic testing, and research, excluding software and informatics solutions.

Leading companies in the molecular diagnostics equipment and reagent market include Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., QIAGEN N.V., and Thermo Fisher Scientific Inc. These companies are strengthening their market positions through continuous advancements in molecular diagnostic technologies, expansion of their equipment and reagent portfolios, and enhancement of testing capabilities across infectious disease, oncology, and genetic testing applications.

The increasing prevalence of infectious diseases is a significant factor driving demand for molecular diagnostics equipment and reagents. Growing disease transmission, the emergence of new pathogens, and recurring outbreaks have heightened the need for rapid and accurate diagnostic testing to enable timely clinical decision-making. According to the National Institutes of Health (NIH), approximately 23 million Americans visit doctors offices or clinics each year seeking treatment for infections, underscoring the substantial burden of infectious diseases on healthcare systems. The rising incidence of respiratory infections is further accelerating the adoption of advanced molecular diagnostic technologies. The Centers for Disease Control and Prevention (CDC) estimated that the 2024–2025 influenza season resulted in 51 million flu-related illnesses, 23 million medical visits, 710,000 hospitalizations, and 45,000 deaths in the U.S.. The CDC also classified the season as having high severity, reflecting the growing public health impact of infectious diseases.  As healthcare providers increasingly prioritize early disease detection, accurate pathogen identification, and outbreak management, demand for molecular diagnostic instruments, assay kits, and reagents continues to expand across clinical and laboratory settings.

Additionally, the rapidly growing elderly population is a key driver for the molecular diagnostics equipment and reagents market, as older individuals are more susceptible to chronic diseases, infectious diseases, cancer, cardiovascular disorders, and genetic conditions that require accurate and timely diagnostic testing. The increasing prevalence of age-associated health conditions is fueling demand for advanced molecular diagnostic technologies that enable early disease detection, disease monitoring, and personalized treatment planning. According to the World Health Organization (WHO), by 2030, one in six people globally will be aged 60 years or older, with the population in this age group increasing from 1 billion in 2020 to 1.4 billion. Furthermore, the global population aged 60 years and above is projected to double to 2.1 billion by 2050, while the number of people aged 80 years or older is expected to triple to 426 million.  The expanding geriatric population is expected to increase diagnostic testing volumes, thereby supporting sustained demand for molecular diagnostic instruments, assay kits, and reagents across healthcare settings.
 

Molecular Diagnostics Equipment and Reagent Market Trends

• Increasing awareness regarding the importance of early disease diagnosis is driving significant growth in the molecular diagnostics equipment and reagent industry. Healthcare organizations and medical professionals are increasingly emphasizing timely detection of infectious diseases, cancer, and genetic disorders, thereby boosting the adoption of molecular diagnostic solutions.
• Additionally, growing patient awareness of preventive healthcare and routine screening is increasing demand for accurate and rapid diagnostic testing. Molecular diagnostics equipment and reagents enable early identification of diseases, supporting improved clinical outcomes and more effective treatment planning.
• Furthermore, continuous technological advancements are transforming the molecular diagnostics landscape. Innovations in polymerase chain reaction (PCR), next-generation sequencing (NGS), and multiplex testing technologies are enhancing diagnostic sensitivity, accuracy, and efficiency, making molecular testing more reliable and accessible.
• For instance, Roche Diagnostics launched the cobas 6800/8800 System, a fully automated molecular diagnostics platform that integrates sample preparation, amplification, and detection into a single workflow. The system provides high-throughput PCR-based testing with enhanced accuracy, efficiency, and scalability. Such technologically advanced solutions help laboratories process larger testing volumes with faster turnaround times, thereby driving the growth of the market.
• Moreover, the integration of automation, artificial intelligence, and point-of-care molecular diagnostic systems is emerging as a major market trend. These advancements streamline laboratory workflows, reduce turnaround times, and expand testing capabilities across healthcare settings, further accelerating market adoption worldwide.

 

 

Molecular Diagnostics Equipment and Reagent Market Analysis

Based on the product type, the molecular diagnostics equipment and reagent market is segmented into instruments and reagents and kits. The reagents and kits segment accounted for the highest market share of 71.9% in 2025.

• Reagents and kits form the operational backbone of molecular diagnostic testing, as they are required for every test performed across infectious disease, oncology, genetic, and prenatal screening applications. The expanding volume of diagnostic procedures and increasing laboratory testing activity continue to create sustained demand for these consumables.
• Furthermore, continuous innovation in assay design, multiplex detection capabilities, and disease-specific testing panels is enhancing diagnostic accuracy and efficiency. The growing preference for standardized and easy-to-use testing solutions among laboratories and healthcare providers is further supporting the adoption of advanced reagents and kits.
• The instruments segment accounted for USD 5.2 billion in 2025 and is projected to expand at a CAGR of 7.9% from 2026 to 2035. The instruments segment is benefiting from the ongoing modernization of diagnostic laboratories and healthcare facilities worldwide. Growing emphasis on rapid disease detection, workflow optimization, and high-throughput testing is encouraging healthcare providers to invest in advanced molecular diagnostic platforms.
• Moreover, technological advancements such as automation, integrated data management, and enhanced analytical performance are increasing the appeal of modern diagnostic instruments. Rising deployment of PCR systems, sequencing platforms, and automated analyzers across clinical and research settings is contributing to the continued expansion of this segment.

Based on technology, the molecular diagnostics equipment and reagent market is segmented into polymerase chain reaction (PCR), hybridization, sequencing, isothermal nucleic acid amplification technology (INAAT), microarrays, and other technologies. The polymerase chain reaction (PCR) segment accounted for the highest market share of 45.5% in 2025. 

• PCR is a molecular diagnostic technology that amplifies and detects specific DNA or RNA sequences to enable accurate disease identification. PCR continues to be the preferred technology across clinical diagnostics owing to its high sensitivity, rapid turnaround time, and broad applicability in detecting infectious diseases, cancer biomarkers, and genetic abnormalities. Its compatibility with both routine and complex testing workflows has supported widespread adoption across healthcare settings.
• Moreover, continuous improvements in real-time PCR, digital PCR, and multiplex PCR platforms are expanding testing capabilities while enhancing operational efficiency. Growing demand for early and precise diagnosis, coupled with increased laboratory testing volumes, continues to drive utilization of PCR-based molecular diagnostic solutions.
• The hybridization segment accounted for USD 1.9 billion in 2025 and is projected to expand at a CAGR of 8% from 2026 to 2035. Hybridization is a molecular diagnostic technique that identifies nucleic acid sequences through the binding of complementary DNA or RNA strands. The technology plays an important role in detecting genetic variations, chromosomal abnormalities, and infectious agents with high specificity. Its ability to support confirmatory testing and targeted molecular analysis has strengthened its utilization in specialized diagnostic applications.
• Moreover, increasing research activities in genomics and molecular biology are expanding the application scope of hybridization technologies. Continued development of advanced probe-based systems is further enhancing diagnostic accuracy and supporting market expansion.
• The sequencing segment accounted for USD 893 million in 2025 and is projected to expand at a CAGR of 6.8% from 2026 to 2035. Growing demand for comprehensive genomic analysis is driving the adoption of sequencing technologies in disease diagnosis and therapeutic decision-making. The technology provides detailed genetic insights that are increasingly valuable in oncology, rare disease detection, and precision medicine initiatives.
• Additionally, ongoing advancements in next-generation sequencing (NGS) platforms are reducing testing costs while improving throughput and data quality. Expanding use of genomic testing in both clinical and research settings continues to fuel growth within this segment.
• The INAAT segment accounted for USD 1.5 billion in 2025 and is projected to expand at a CAGR of 7.1% from 2026 to 2035. INAAT is a molecular diagnostic method that amplifies nucleic acids at a constant temperature without requiring thermal cycling. The technology is gaining recognition for its ability to deliver rapid and cost-effective results while simplifying testing procedures. Its suitability for decentralized and point-of-care diagnostics is supporting increased adoption, particularly in resource-limited healthcare environments.
• Furthermore, rising demand for portable diagnostic solutions and faster disease detection is encouraging investment in INAAT-based platforms. The technology's operational simplicity and reduced infrastructure requirements are contributing to its expanding market presence.
• The microarrays segment accounted for USD 2.4 billion in 2025 and is projected to expand at a CAGR of 6.5% from 2026 to 2035. Their high-throughput analytical capability makes them valuable for large-scale genomic studies, biomarker discovery, and disease profiling applications. Increasing use of personalized medicine approaches is driving demand for technologies capable of evaluating multiple biological targets efficiently.
• Moreover, advancements in data analytics and molecular biology are improving the reliability and clinical relevance of microarray testing. Growing interest in comprehensive molecular characterization is supporting broader utilization across research and diagnostic laboratories.

 

Based on application, the molecular diagnostics equipment and reagent market is segmented into infectious disease diagnostics, genetic disease testing, oncology testing, and other applications. The infectious disease diagnostics market is further bifurcated into, COVID-19, flu, respiratory syncytial virus (RSV), tuberculosis, CT/NG, HIV, Hepatitis C, Hepatitis B, and other infectious disease diagnostics. The infectious disease diagnostics segment accounted for the highest market share of 71.8% in 2025.

• Infectious disease diagnostics involves the detection and identification of bacterial, viral, fungal, and parasitic infections using molecular testing techniques. The segment continues to benefit from the growing burden of infectious diseases and the increasing need for rapid, accurate, and early diagnosis. Healthcare providers are increasingly utilizing molecular diagnostics to support timely treatment decisions, improve patient outcomes, and strengthen disease surveillance efforts.
• Furthermore, expanding screening programs, rising awareness of disease prevention, and the growing adoption of point-of-care testing solutions are accelerating demand for infectious disease molecular tests. Continuous development of advanced assays capable of detecting multiple pathogens simultaneously is further supporting segment growth.
• The genetic disease testing segment accounted for USD 1.5 billion in 2025 and is projected to expand at a CAGR of 8.2% from 2026 to 2035. Genetic disease testing focuses on identifying inherited mutations and genetic abnormalities associated with various disorders and health conditions. The growing emphasis on preventive healthcare and early risk assessment is driving demand for genetic testing solutions. Healthcare professionals are increasingly incorporating molecular diagnostics into clinical practice to enable timely intervention and personalized patient management.
• Additionally, advancements in genomic technologies and increasing accessibility of genetic testing services are encouraging broader adoption across healthcare systems. Rising awareness regarding hereditary diseases and family health history is also contributing to the continued expansion of this segment.
• The oncology segment accounted for USD 1.4 billion in 2025 and is projected to expand at a CAGR of 7.9% from 2026 to 2035. Oncology testing utilizes molecular diagnostic methods to detect cancer-related biomarkers, mutations, and genetic alterations. Increasing cancer incidence worldwide is creating substantial demand for precise diagnostic tools that support early detection and targeted treatment selection. Molecular oncology testing enables clinicians to better understand tumor characteristics, facilitating more informed therapeutic decisions.
• Moreover, the growing adoption of precision medicine and companion diagnostics is strengthening the role of molecular testing in cancer care. Continued innovation in biomarker-based diagnostics and personalized treatment approaches is further driving growth within this segment.

Based on test setting, the molecular diagnostics equipment and reagent market is segmented into laboratory-based tests, and point-of-care tests. The laboratory-based tests segment accounted for the highest market share of 62.2% in 2025.

• Laboratory-based tests are molecular diagnostic tests performed in centralized laboratories using advanced instruments and specialized workflows. The segment benefits from the availability of sophisticated diagnostic infrastructure, skilled personnel, and high-throughput testing capabilities that support accurate detection of a wide range of diseases. Healthcare providers continue to rely on laboratory-based molecular testing for complex analyses requiring high sensitivity and comprehensive result interpretation.
• For instance, Hologic offers the Panther System, a laboratory-based, fully automated molecular diagnostics platform that enables clinical laboratories to perform sample preparation, nucleic acid amplification, and detection within a single integrated workflow. Its automation, scalability, and ability to process large test volumes with faster turnaround times help improve laboratory efficiency and diagnostic accuracy, thereby driving the growth of the market.
• Furthermore, increasing testing volumes associated with infectious diseases, oncology, and genetic disorders are encouraging laboratories to adopt automated and integrated diagnostic platforms. Continuous investments in laboratory modernization and workflow optimization are further strengthening demand for laboratory-based molecular testing services.

• The point-of-care tests segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 7.8% over the forecast period. point-of-care tests are molecular diagnostic tests performed near the patient, enabling rapid clinical decision-making without requiring centralized laboratory processing. The Point of care tests are gaining traction as healthcare systems prioritize faster diagnosis and immediate treatment initiation. Growing demand for decentralized healthcare delivery is accelerating the adoption of portable and user-friendly molecular diagnostic devices across clinics, emergency departments, and community healthcare settings.
• For instance, Cepheid offers the GeneXpert System, a point-of-care (POC)-based molecular diagnostics platform that enables healthcare providers to perform automated sample preparation, nucleic acid amplification, and detection within a self-contained cartridge system. Designed for near-patient testing, the platform delivers rapid PCR-based results with minimal hands-on time, high accuracy, and a scalable modular architecture suitable for hospitals, clinics, and decentralized care settings. Its ability to provide fast and reliable diagnostic results at the point of care helps improve clinical decision-making, reduce treatment delays, and enhance patient outcomes, thereby driving the growth of the market.

Based on the end use, the molecular diagnostics equipment and reagent market is segmented into hospitals and clinics, diagnostic Laboratories, and other end users. The hospitals and clinics segment accounted for the highest market share of 45.9% in 2025.

• Hospitals and clinics utilize molecular diagnostic tests for disease detection, treatment planning, patient monitoring, and routine clinical decision-making. Hospitals benefit from the growing integration of molecular diagnostics into standard patient care pathways, particularly for infectious disease detection, cancer diagnosis, and genetic testing. Rising patient admissions and increasing demand for accurate diagnostic outcomes are encouraging healthcare facilities to expand their molecular testing capabilities.
• Availability of advanced diagnostic infrastructure and the growing adoption of precision medicine approaches are supporting greater utilization of molecular diagnostic technologies within hospitals and clinics. Continuous investments in improving patient care quality and reducing diagnostic turnaround times are further contributing to segment growth.
• The diagnostic laboratories segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 8.1% over the forecast period. The increasing complexity of molecular testing and the need for highly accurate results are driving greater reliance on dedicated diagnostic laboratories. Their ability to process large test volumes efficiently makes them an essential component of the molecular diagnostics ecosystem.
• Growing demand for specialized genomic, oncology, and infectious disease testing is encouraging laboratories to adopt automated and next-generation molecular diagnostic solutions. Expansion of reference laboratory networks and investments in laboratory modernization continue to support adoption across this segment.

North America Molecular Diagnostics Equipment and Reagent Market

The North America region accounted for 42.4% of the molecular diagnostics equipment and reagent industry in 2025. The market in North America is experiencing robust expansion.

• The U.S. market market size reached USD 7.1 billion in 2025, growing from USD 6.6 billion in 2024, and is anticipated to grow at a CAGR of 7.5% from 2026 to 2035.
• North America continues to witness substantial demand for molecular diagnostic testing due to the significant burden of infectious diseases such as HIV. Approximately 1.2 million people in the U.S. are living with HIV, and nearly one in eight individuals remain unaware of their infection status, highlighting the need for accurate and early diagnostic solutions. This is driving increased adoption of molecular diagnostics technologies that enable rapid and reliable disease detection.
• Furthermore, healthcare providers and public health agencies across the region are placing greater emphasis on disease surveillance, routine screening, and early intervention strategies. Molecular diagnostic tests offer high sensitivity and specificity, making them valuable tools for identifying infections at an early stage and supporting timely treatment decisions.
• Additionally, growing investments in advanced diagnostic infrastructure and expanding access to molecular testing services are further supporting market growth. As awareness regarding infectious disease prevention and management continues to increase, demand for molecular diagnostics equipment and reagents is expected to remain strong throughout North America.

Europe Molecular Diagnostics Equipment and Reagent Market

Europe market accounted for USD 4.4 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• The increasing prevalence of cancer across Europe is a key factor driving growth in the Europe molecular diagnostics equipment and reagent industry. According to the World Health Organization (WHO), more than 3.7 million new cancer cases and 1.9 million cancer-related deaths occur annually in Europe, highlighting the substantial need for advanced diagnostic solutions. This is accelerating the adoption of molecular diagnostic technologies for early and accurate cancer detection.
• Furthermore, healthcare providers are increasingly utilizing molecular diagnostics to identify cancer-specific biomarkers, genetic mutations, and tumor characteristics that support personalized treatment strategies. The growing emphasis on precision medicine is strengthening demand for advanced molecular diagnostic equipment and specialized reagents across the region.

Asia Pacific Molecular Diagnostics Equipment and Reagent Market

The Asia Pacific region is projected to show a lucrative growth of about 8.1% during the forecast period.

• The rapidly expanding elderly population across Asia Pacific is driving demand for molecular diagnostic testing, as older individuals are more susceptible to chronic diseases, cancer, infectious diseases, and genetic disorders. The growing need for early and accurate disease detection is encouraging healthcare providers to adopt advanced molecular diagnostics technologies.
• For instance, India's senior citizen population is projected to reach approximately 230 million by 2036, accounting for nearly 15% of the country's total population. This demographic shift is expected to increase the number of age-related disease cases, creating greater demand for molecular diagnostics equipment and reagents for disease screening, monitoring, and personalized treatment planning.
• Governments and healthcare organizations across the region are expanding healthcare services targeted toward aging populations. As the focus on preventive healthcare and precision medicine continues to strengthen, the adoption of molecular diagnostic solutions is expected to increase significantly, supporting market growth across Asia Pacific.

Latin America Molecular Diagnostics Equipment and Reagent Market 

The Latin America market is experiencing robust growth over the analysis timeframe.

• The rising prevalence of infectious diseases across Latin America is a key factor driving growth in the Latin America molecular diagnostics equipment and reagent industry. Increasing cases of dengue, tuberculosis, HIV, hepatitis, and other infectious diseases are creating substantial demand for rapid and accurate molecular diagnostic testing solutions.
• Healthcare authorities across the region are strengthening disease surveillance and screening initiatives to improve outbreak management and patient outcomes. The ability of molecular diagnostics equipment and reagents to provide sensitive and reliable pathogen detection is accelerating their adoption across hospitals, laboratories, and diagnostic centers.

Middle East and Africa Molecular Diagnostics Equipment and Reagent Market 

The Middle East and Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• Technological advancements and increasing awareness regarding the importance of early disease diagnosis are driving growth in the Middle East & Africa market. Healthcare providers are increasingly adopting molecular diagnostic technologies to enable early detection of infectious diseases, cancer, and genetic disorders, thereby improving treatment outcomes.
• Moreover, innovations in PCR systems, automated molecular diagnostic platforms, and multiplex testing solutions are enhancing testing accuracy, speed, and laboratory efficiency. These advancements are encouraging healthcare facilities to modernize their diagnostic capabilities and expand access to molecular testing services.

Molecular Diagnostics Equipment and Reagent Market Share

• The top five players, F. Hoffmann-La Roche Ltd., Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific Inc., and QIAGEN N.V., collectively account for approximately 60% of the molecular diagnostics equipment and reagent industry. Their strong market positions are supported by extensive molecular diagnostics product portfolios, advanced PCR and molecular testing platforms, broad reagent and assay offerings, well-established global distribution networks, and continuous investments in automation, infectious disease diagnostics, precision medicine, and next-generation molecular diagnostic technologies.
• Molecular diagnostics equipment and reagent manufacturers, diagnostic solution providers, and healthcare institutions are increasingly focusing on technological advancements to enhance the accuracy, speed, and clinical value of molecular testing. Key developments include innovations in polymerase chain reaction (PCR), next-generation sequencing (NGS), isothermal nucleic acid amplification technologies, multiplex molecular assays, and automated diagnostic platforms. Additionally, advancements in laboratory automation, integrated data management systems, and artificial intelligence-assisted result analysis are improving testing efficiency, workflow optimization, and diagnostic reliability. Continuous investments in advanced molecular diagnostic instruments and reagents are supporting broader adoption across hospitals, diagnostic laboratories, and research facilities, thereby driving market growth.
• Market participants, including molecular diagnostics companies, healthcare providers, diagnostic laboratories, and research organizations, are actively pursuing strategic collaborations to expand the application scope of molecular diagnostics equipment and reagents. Partnerships with hospitals, public health agencies, biotechnology firms, and pharmaceutical companies are facilitating the development of advanced diagnostic assays and expanding access to molecular testing services. Furthermore, collaborations with academic institutions and research centers are accelerating innovation in infectious disease diagnostics, oncology testing, genetic disease assessment, and precision medicine applications. These initiatives are strengthening clinical validation, increasing adoption of molecular diagnostics technologies, and expanding their use across diverse healthcare settings, thereby supporting the overall growth of the market.

Molecular Diagnostics Equipment and Reagent Market Companies

Few of the prominent players operating in the molecular diagnostics equipment and reagent industry include:

• Abbott Laboratories
• Agilent Technologies
• Becton, Dickinson and Company (BD)
• Biocartis
• bioMérieux
• Bio-Rad Laboratories
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Huwel Lifesciences
• Illumina, Inc.
• QIAGEN N.V.
• QuidelOrtho Corporation
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

 

•  F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. is a leading participant in the market, offering a comprehensive portfolio of molecular testing solutions for infectious diseases, oncology, and genetic disorders. The company’s strong focus on automation, innovation, and diagnostic accuracy supports its global market leadership.

• Danaher Corporation

Danaher Corporation maintains a strong presence in the molecular diagnostics equipment and reagent market through its advanced molecular testing solutions. The company emphasizes rapid and accurate disease detection, supporting a wide range of clinical applications while expanding access to molecular diagnostics across diverse healthcare settings.

• QIAGEN N.V.

QIAGEN N.V. specializes in molecular testing technologies that support disease detection, genomic analysis, and precision healthcare. Its extensive portfolio of molecular diagnostics equipment and reagents, combined with a strong focus on sample preparation and assay development, supports growing adoption across laboratories and healthcare institutions.

Molecular Diagnostics Equipment and Reagent Industry News

• In May 2022, Abbott secured FDA clearance for its Alinity m STI Assay, a diagnostic test capable of detecting and differentiating four prevalent sexually transmitted infections (STIs): Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG). The test requires only a single swab or urine sample, which can be collected by a clinician or the patient. Designed to run on Abbott’s Alinity m system, the company’s advanced high-volume molecular diagnostic instrument, the assay utilizes highly sensitive PCR technology for precise infectious disease detection. This product launch enhanced diagnostic efficiency, improved patient outcomes, expanded Abbott’s molecular diagnostics portfolio, and contributed to revenue growth.

The molecular diagnostics equipment and reagent market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:
 

Market, By Product Type

• Instruments
• Reagents and kits

Market, By Technology

• Polymerase chain reaction (PCR)
• Hybridization
• Sequencing
• Isothermal nucleic acid amplification technology (INAAT)
• Microarrays
• Other technologies

Market, By Application

• Infectious disease diagnostics
  • COVID-19
  • Flu
  • Respiratory syncytial virus (RSV)
  • Tuberculosis
  • CT/NG
  • HIV
  • Hepatitis C
  • Hepatitis B
  • Other infectious disease diagnostics
• Genetic disease testing
• Oncology testing
• Other applications

Market, By Test Setting

• Laboratory-based tests
• Point-of-Care (POC) tests

Market, By End Use

• Hospitals and clinics
• Diagnostic Laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE